CRISPR_Logo.jpg
CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies
August 22, 2017 07:30 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR_Logo.jpg
CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
May 08, 2017 08:00 ET | CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR_Logo.jpg
CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference
March 30, 2017 08:00 ET | CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology...
CRISPR_Logo.jpg
CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing
March 28, 2017 08:00 ET | CRISPR Therapeutics AG
- Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells BASEL, Switzerland, March 28, 2017 (GLOBE...
CRISPR_Logo.jpg
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
March 14, 2017 07:00 ET | CRISPR Therapeutics AG
BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative...
CRISPR_Logo.jpg
CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference
March 02, 2017 16:30 ET | CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology...
CRISPR_Logo.jpg
CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation
February 28, 2017 08:00 ET | CRISPR Therapeutics AG
Experienced leader with extensive experience in immuno-oncologyDedicated unit in immuno-oncology to accelerate efforts BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) --...
CRISPR_Logo.jpg
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
December 16, 2016 08:00 ET | CRISPR Therapeutics AG
BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou...